Revolution Medicines' Daraxonrasib Shows Dramatic Survival Benefit in Metastatic Pancreatic Cancer

Revolution Medicines (NASDAQ: RVMD) announced on April 13, 2026 that its oral RAS inhibitor, daraxonrasib, produced a st...

Read story →